CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.
The U.S. Shipbuilding Base has Withered Since the 80s; Latest CPA Report Examines What’s Needed to Bring it Back
The latest Section 232 announcements expand the list of ongoing investigations into imported goods that could be exposed to higher tariffs.
As proof that no company can match China on price, Chinese producers of active pharmaceutical ingredients (APIs) and the key starting materials (KSMs) used to make them are slashing prices by up to 50%. Not even low-cost India – one of the largest importers of Chinese KSMs – can compete at those levels.
Findings Indicate that Copper Products Remain Essential to U.S. Economy and National Security as Trump Administration Seeks to Protect and Enhance Industry
The closure of the de minimis loophole – which went into effect at midnight – stops the descent into eCommerce lawlessness characterized by the rise in platforms like Temu and Shein, and the fact that judgment-proof overseas retailers now make up the majority of vendors on Amazon’s U.S. store.
Ruling Clears the Way for Retroactive Tariffs on Billions in Illegally Imported Chinese Solar Equipment
Aurobindo Pharma’s proposed $5.5 billion acquisition of Prague-based Zentiva poses an unacceptable risk to Europe’s and America’s pharmaceutical security. CPA is calling on the European Union (EU), including Czech authorities and European Commission competition regulators, to reject the transaction.
